Lipoxen's Polysialylated G-CSF StimuXen™
Technology Granted European Patent
Lipoxen plc announces that it has been granted patents for its
Polysialylated GCSF StimuXen™ Technology in six European
territories, including the UK, Germany, France, Spain, Italy and
Switzerland. more...
Lipoxen is a leading UK based biopharmaceutical company
providing specialist delivery solutions to improve the
efficacy and performance of drugs and vaccines in a variety of
important medical areas.
Working with some of the largest pharmaceutical organisations in
the world, Lipoxen provides leading edge expertise in the
development of a whole new generation of drugs and vaccines.
An advanced enabling technology that uses novel polymer and liposome based-constructs:
A portfolio with multi-billion dollar potential
Lipoxen's supergenerics product pipeline is based on its drug and vaccine delivery proprietary technologies. Our unique delivery technologies have the capacity to create new high-value, differentiated proprietary products. READ MORE...
The information in this website has been disclosed for the purposes of Rule 26 of the AIM Rules for companies (February 2007) and was last updated on 08 February 2010.